<s id="wsj_1542.1"> 28
1 	 0 	 NP[nb]/N 	 1 	 Food The
1 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 Food said
4 	 0 	 NP[nb]/N 	 1 	 Administration The
4 	 3 	 N/N 	 1 	 Administration Drug
4 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 Administration said
9 	 6 	 N/N 	 1 	 Corp. American
9 	 7 	 N/N 	 1 	 Corp. Home
9 	 8 	 N/N 	 1 	 Corp. Products
9 	 10 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Corp. agreed
9 	 12 	 (S[b]\NP)/NP 	 1 	 Corp. recall <XB>
10 	 5 	 (S[dcl]\NP)/S[dcl] 	 2 	 agreed said
11 	 10 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to agreed
12 	 11 	 (S[to]\NP)/(S[b]\NP) 	 2 	 recall to
15 	 12 	 (S[b]\NP)/NP 	 2 	 drugs recall
15 	 13 	 N/N 	 1 	 drugs certain
15 	 14 	 N/N 	 1 	 drugs generic
15 	 16 	 (NP\NP)/(S[dcl]\NP) 	 1 	 drugs that
15 	 17 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 drugs were <XB>
15 	 18 	 S[pss]\NP 	 1 	 drugs produced <XB>
17 	 16 	 (NP\NP)/(S[dcl]\NP) 	 2 	 were that
18 	 17 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 produced were
18 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 produced by
23 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 unit by
23 	 20 	 NP[nb]/N 	 1 	 unit its
23 	 21 	 N/N 	 1 	 unit Quantum
23 	 22 	 N/N 	 1 	 unit Pharmics
23 	 24 	 (NP\NP)/NP 	 1 	 unit in
25 	 24 	 (NP\NP)/NP 	 2 	 Amityville in
27 	 24 	 (NP\NP)/NP 	 2 	 N.Y in
<\s>
<s id="wsj_1542.2"> 22
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Quantum stopped
0 	 2 	 (S[ng]\NP)/NP 	 1 	 Quantum shipping <XB>
2 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 shipping stopped
2 	 6 	 (S\NP)\(S\NP) 	 2 	 shipping month
2 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 shipping following
4 	 2 	 (S[ng]\NP)/NP 	 2 	 drugs shipping
4 	 3 	 NP[nb]/N 	 1 	 drugs the
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 month last
11 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 investigation following
11 	 9 	 NP[nb]/N 	 1 	 investigation a
11 	 10 	 N/N 	 1 	 investigation federal
11 	 12 	 (S[ng]\NP)/NP 	 1 	 investigation regarding <XB>
13 	 12 	 (S[ng]\NP)/NP 	 2 	 information regarding
13 	 16 	 (S[dcl]\NP)/NP 	 2 	 information supplied <XU>
15 	 14 	 NP[nb]/N 	 1 	 company the
15 	 16 	 (S[dcl]\NP)/NP 	 1 	 company supplied
15 	 18 	 (S[b]\NP)/NP 	 1 	 company obtain <XB>
18 	 17 	 (S[to]\NP)/(S[b]\NP) 	 2 	 obtain to
21 	 18 	 (S[b]\NP)/NP 	 2 	 approvals obtain
21 	 19 	 N/N 	 1 	 approvals three
21 	 20 	 N/N 	 1 	 approvals drug
<\s>
<s id="wsj_1542.3"> 48
1 	 0 	 NP[nb]/N 	 1 	 FDA The
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 FDA requested
2 	 18 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 requested because
4 	 2 	 (S[dcl]\NP)/NP 	 2 	 recall requested
4 	 3 	 NP[nb]/N 	 1 	 recall the
4 	 5 	 (NP\NP)/NP 	 1 	 recall of
6 	 7 	 (NP[nb]/N)\NP 	 2 	 Quantum 's
17 	 5 	 (NP\NP)/NP 	 2 	 capsules of
17 	 7 	 (NP[nb]/N)\NP 	 1 	 capsules 's
17 	 8 	 N/N 	 1 	 capsules mioxidil
17 	 9 	 N/N 	 1 	 capsules tablets
17 	 11 	 N/N 	 1 	 capsules chlorazepate
17 	 12 	 N/N 	 1 	 capsules dipotassium
17 	 13 	 N/N 	 1 	 capsules tablets
17 	 15 	 N/N 	 1 	 capsules meclofenamate
17 	 16 	 N/N 	 1 	 capsules sodium
20 	 21 	 (S[dcl]\NP)/S[dcl] 	 1 	 it said
24 	 23 	 NP[nb]/N 	 1 	 size the
24 	 25 	 (NP\NP)/NP 	 1 	 size of
24 	 36 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 size was
24 	 40 	 (S[pss]\NP)/PP 	 1 	 size misrepresented <XB>
28 	 25 	 (NP\NP)/NP 	 2 	 runs of
28 	 26 	 NP[nb]/N 	 1 	 runs the
28 	 27 	 N/N 	 1 	 runs production
28 	 29 	 S[pss]\NP 	 1 	 runs submitted <XB>
28 	 33 	 (S[b]\NP)/NP 	 1 	 runs gain <XB>
29 	 30 	 ((S\NP)\(S\NP))/NP 	 2 	 submitted for
31 	 30 	 ((S\NP)\(S\NP))/NP 	 3 	 testing for
33 	 32 	 (S[to]\NP)/(S[b]\NP) 	 2 	 gain to
35 	 33 	 (S[b]\NP)/NP 	 2 	 approval gain
35 	 34 	 N/N 	 1 	 approval FDA
36 	 18 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 was because
36 	 37 	 ((S\NP)\(S\NP))/NP 	 2 	 was in
39 	 37 	 ((S\NP)\(S\NP))/NP 	 3 	 case in
39 	 38 	 NP[nb]/N 	 1 	 case each
40 	 36 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 misrepresented was
41 	 40 	 (S[pss]\NP)/PP 	 2 	 as misrepresented
43 	 41 	 PP/(S[adj]\NP) 	 1 	 larger as
43 	 42 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 larger much
43 	 44 	 ((S[adj]\NP)\(S[adj]\NP))/S[dcl] 	 2 	 larger than
45 	 47 	 S[dcl]\NP 	 1 	 it was
47 	 44 	 ((S[adj]\NP)\(S[adj]\NP))/S[dcl] 	 3 	 was than
47 	 46 	 (S\NP)/(S\NP) 	 2 	 was actually
<\s>
<s id="wsj_1542.4"> 38
2 	 0 	 N/N 	 1 	 Products American
2 	 1 	 N/N 	 1 	 Products Home
2 	 4 	 S[pss]\NP 	 1 	 Products based <XB>
2 	 9 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Products agreed
2 	 11 	 (S[b]\NP)/NP 	 1 	 Products recall <XB>
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
7 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 York in
7 	 6 	 N/N 	 1 	 York New
10 	 9 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to agreed
11 	 10 	 (S[to]\NP)/(S[b]\NP) 	 2 	 recall to
11 	 24 	 ((S\NP)\(S\NP))/PP 	 2 	 recall because
14 	 11 	 (S[b]\NP)/NP 	 2 	 products recall
14 	 12 	 N/N 	 1 	 products four
14 	 13 	 N/N 	 1 	 products other
16 	 11 	 (S[b]\NP)/NP 	 2 	 trazadone recall
18 	 11 	 (S[b]\NP)/NP 	 2 	 doxepin recall
20 	 11 	 (S[b]\NP)/NP 	 2 	 diazepam recall
22 	 11 	 (S[b]\NP)/NP 	 2 	 lorazapam recall
25 	 24 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
26 	 25 	 PP/NP 	 1 	 concerns of
26 	 27 	 (NP\NP)/NP 	 1 	 concerns about
28 	 27 	 (NP\NP)/NP 	 2 	 data about
28 	 29 	 S[pss]\NP 	 1 	 data submitted <XB>
29 	 30 	 ((S\NP)\(S\NP))/NP 	 2 	 submitted in
29 	 35 	 ((S\NP)\(S\NP))/NP 	 2 	 submitted before
34 	 30 	 ((S\NP)\(S\NP))/NP 	 3 	 applications in
34 	 31 	 NP[nb]/N 	 1 	 applications their
34 	 32 	 N/N 	 1 	 applications original
34 	 33 	 N/N 	 1 	 applications approval
37 	 35 	 ((S\NP)\(S\NP))/NP 	 3 	 FDA before
37 	 36 	 NP[nb]/N 	 1 	 FDA the
<\s>
<s id="wsj_1542.5"> 12
2 	 0 	 NP[nb]/N 	 1 	 problems No
2 	 1 	 N/N 	 1 	 problems safety
2 	 3 	 (NP\NP)/NP 	 1 	 problems with
2 	 6 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 problems are
2 	 7 	 S[pss]\NP 	 1 	 problems known <XB>
5 	 3 	 (NP\NP)/NP 	 2 	 products with
5 	 4 	 NP[nb]/N 	 1 	 products the
6 	 11 	 (S[dcl]\S[dcl])\NP 	 1 	 are said
7 	 6 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 known are
10 	 9 	 NP[nb]/N 	 1 	 FDA the
10 	 11 	 (S[dcl]\S[dcl])\NP 	 2 	 FDA said
<\s>
<s id="wsj_1542.6"> 13
2 	 0 	 NP[nb]/N 	 1 	 spokesperson An
2 	 1 	 N/N 	 1 	 spokesperson FDA
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 spokesperson said
5 	 4 	 NP[nb]/N 	 1 	 drugs the
5 	 6 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 drugs are
5 	 8 	 S[adj]\NP 	 1 	 drugs available <XB>
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 are said
6 	 7 	 (S\NP)\(S\NP) 	 2 	 are still
6 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 are under
8 	 6 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 available are
12 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 names under
12 	 10 	 N/N 	 1 	 names other
12 	 11 	 N/N 	 1 	 names brand
<\s>
<s id="wsj_1542.7"> 30
1 	 0 	 (S/S)/(S/S) 	 2 	 month Last
5 	 3 	 N/N 	 1 	 Products American
5 	 4 	 N/N 	 1 	 Products Home
5 	 6 	 (S[dcl]\NP)/S[dcl] 	 1 	 Products said
6 	 1 	 S/S 	 1 	 said month
7 	 8 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 it was
7 	 9 	 (S[ng]\NP)/NP 	 1 	 it suspending <XB>
8 	 6 	 (S[dcl]\NP)/S[dcl] 	 2 	 was said
9 	 8 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 suspending was
9 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 suspending pending
10 	 9 	 (S[ng]\NP)/NP 	 2 	 production suspending
10 	 13 	 (NP\NP)/NP 	 1 	 production of
12 	 9 	 (S[ng]\NP)/NP 	 2 	 distribution suspending
12 	 13 	 (NP\NP)/NP 	 1 	 distribution of
15 	 13 	 (NP\NP)/NP 	 2 	 21 of
15 	 14 	 NP[nb]/N 	 1 	 21 all
15 	 16 	 (NP\NP)/NP 	 1 	 21 of
17 	 18 	 (NP[nb]/N)\NP 	 2 	 Quantum 's
21 	 16 	 (NP\NP)/NP 	 2 	 products of
21 	 18 	 (NP[nb]/N)\NP 	 1 	 products 's
21 	 19 	 N/N 	 1 	 products generic
21 	 20 	 N/N 	 1 	 products drug
24 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 completion pending
24 	 23 	 NP[nb]/N 	 1 	 completion the
24 	 25 	 (NP\NP)/NP 	 1 	 completion of
29 	 25 	 (NP\NP)/NP 	 2 	 audit of
29 	 26 	 NP[nb]/N 	 1 	 audit an
29 	 27 	 N/N 	 1 	 audit exhaustive
29 	 28 	 N/N 	 1 	 audit internal
<\s>
<s id="wsj_1542.8"> 20
0 	 3 	 (S[dcl]\NP)/NP 	 1 	 It closed
3 	 1 	 (S\NP)/(S\NP) 	 2 	 closed also
3 	 2 	 (S\NP)/(S\NP) 	 2 	 closed temporarily
3 	 6 	 ((S\NP)\(S\NP))/PP 	 2 	 closed because
4 	 3 	 (S[dcl]\NP)/NP 	 2 	 Quantum closed
7 	 6 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
10 	 7 	 PP/NP 	 1 	 investigation of
10 	 8 	 NP[nb]/N 	 1 	 investigation the
10 	 9 	 N/N 	 1 	 investigation internal
10 	 12 	 NP\NP 	 1 	 investigation as
10 	 13 	 NP\NP 	 1 	 investigation well
10 	 14 	 NP\NP 	 1 	 investigation as
10 	 17 	 ((NP\NP)/N)\NP 	 1 	 investigation 's
16 	 15 	 NP[nb]/N 	 1 	 FDA the
16 	 17 	 ((NP\NP)/N)\NP 	 3 	 FDA 's
19 	 17 	 ((NP\NP)/N)\NP 	 2 	 inquiry 's
19 	 18 	 N/N 	 1 	 inquiry ongoing
<\s>
<s id="wsj_1542.9"> 19
6 	 0 	 (S/S)/NP 	 2 	 trading In
6 	 1 	 N/N 	 1 	 trading New
6 	 2 	 N/N 	 1 	 trading York
6 	 3 	 N/N 	 1 	 trading Stock
6 	 4 	 N/N 	 1 	 trading Exchange
6 	 5 	 N/N 	 1 	 trading composite
10 	 8 	 N/N 	 1 	 Products American
10 	 9 	 N/N 	 1 	 Products Home
10 	 11 	 S[dcl]\NP 	 1 	 Products rose
11 	 0 	 (S/S)/NP 	 1 	 rose In
11 	 13 	 (S\NP)\(S\NP) 	 2 	 rose cents
11 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
11 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 rose on
13 	 12 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 cents 75
15 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
16 	 15 	 N/N[num] 	 1 	 105 $
18 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 Friday on
<\s>
